Correction to: Endocrine

https://doi.org/10.1007/s12020-019-02160-z

The original version of this article unfortunately discovered two errors in the dataset. Instead of only including patients with a primary diagnosis of hyponatremia some cases with hyponatremia as a secondary diagnosis had been included. When corrected, the number of cases admitted with a primary diagnosis of hyponatremia were 11,213 instead of 14,359 as reported in the article, and thus the number of matched controls were 44,801 instead of 57,382. The second error relates to the index date which is in fact the discharge date, not the admission date as initially thought.

However, these errors have had a marginal impact on the results, with magnitudes and direction of associations for adjusted odds ratios much the same after correction. The corrected (italic) and incorrect (bold) odds ratios are presented in the table below to demonstrate the changes in estimates.

 

Newly initiated glucose-lowering medication CORRECTED Adj. OR (95% CI)

Newly initiated glucose-lowering medication INCORRECT Adj. OR (95% CI)

Ongoing glucose-lowering medication CORRECTED Adj. OR (95% CI)

Ongoing glucose-lowering medication INCORRECT Adj. OR (95% CI)

Insulins

0.96 (0.57; 1.59)

1.17 (0.81; 1.68)

0.63 (0.55; 0.72)

0.54 (0.48; 0.61)

Metformin

0.72 (0.44; 1.16)

0.67 (0.46; 1.01)

0.86 (0.77; 0.97)

0.82 (0.73; 0.91)

Sulfonylurea

0.65 (0.28; 1.38)

0.92 (0.56; 1.46)

0.90 (0.75; 1.07)

0.78 (0.66; 0.92)

DPP4-inhibitors

1.00 (0.23; 3.18)

1.18 (0.40; 3.07)

0.77 (0.44; 1.31)

0.72 (0.42; 1.19)

GLP1-analogues

2.26 (0.53; 8.70)

2.36 (0.54; 8.90)

0.17 (0.04; 0.54)

0.17 (0.04; 0.52)

Thiazolidinediones

3.18 (0.09; 113)

4.69 (0.39; 58.36)

0.76 (0.36; 1.50)

0.73 (0.38; 1.34)

Meglitinides

0.16 (0.02; 0.87)

0.93 (0.32; 2.53)

0.77 (0.49; 1.16)

0.72 (0.48; 1.06)

Any glucose-lowering medication

0.83 (0.52; 1.30)

0.87 (0.63; 1.18)

0.69 (0.63; 0.75)

0.62 (0.57; 0.67)